Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.22 USD | -1.63% | -8.86% | -53.54% |
May. 30 | Top Premarket Gainers | MT |
May. 29 | Jaguar Health Expands Out-licensing Agreement With Magdalena Biosciences | MT |
Financials (USD)
Sales 2024 * | 15.11M | Sales 2025 * | 22.66M | Capitalization | 20.63M |
---|---|---|---|---|---|
Net income 2024 * | -26M | Net income 2025 * | -21M | EV / Sales 2024 * | 1.37 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.91 x |
P/E ratio 2024 * |
-0.78
x | P/E ratio 2025 * |
-1
x | Employees | 49 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.62% |
Latest transcript on Jaguar Health, Inc.
1 day | -1.63% | ||
1 week | -8.86% | ||
1 month | -67.24% | ||
3 months | +19.21% | ||
6 months | -80.12% | ||
Current year | -53.54% |
Managers | Title | Age | Since |
---|---|---|---|
Lisa Conte
FOU | Founder | 65 | 13-06-05 |
Carol Lizak
DFI | Director of Finance/CFO | 60 | 19-04-30 |
Chief Tech/Sci/R&D Officer | 60 | 17-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lisa Conte
FOU | Founder | 65 | 13-06-05 |
James Bochnowski
CHM | Chairman | 80 | 14-01-31 |
John Micek
BRD | Director/Board Member | 71 | 16-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 4.22 | -1.63% | 826,954 |
24-05-30 | 4.29 | -1.61% | 2,520,833 |
24-05-29 | 4.36 | +8.19% | 2,155,720 |
24-05-28 | 4.03 | -12.96% | 1,359,868 |
24-05-24 | 4.63 | -9.75% | 1,203,516 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.54% | 20.63M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- JAGX Stock